Amarin Corporation plc: Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
DUBLIN, Ireland and BRIDGEWATER, N.J., July 26, 2023 Amarin Corporation plc today announced the acceptance of funded research for presentation at the European Society of Cardiology Congress,.
Amarin Corp. (AMRN) Latest Research Evaluating Clinical Benefits of VASCEPA/VAZKEPA to be Presented at ESC Congress streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The PANTHER meta-analysis of trials comparing aspirin with clopidogrel or ticagrelor as antiplatelet monotherapy in coronary artery disease patients suggest that P2Y12 inhibitor therapy is more effective.